June 18, 2015—The 340B program proposed rule formally published yesterday would give the Department of Health and Human Services Office of Inspector General responsibility for administering financial sanctions on drugmakers that overcharge providers knowingly and intentionally.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)